Perimeter Introduces Claire™ OCT+AI for Breast Cancer Surgery at ASBrS 2026

Perimeter Medical Imaging AI, Inc. has introduced its new Claire™ OCT+AI system at the 27th Annual Meeting of the American Society of Breast Surgeons (ASBrS), held from April 29 to May 3, 2026, in Seattle, Washington. This system is notable for being the first AI-enabled imaging device in the United States approved by the FDA for intraoperative breast cancer margin assessment.

Claire™ OCT+AI combines Perimeter's proprietary artificial intelligence technology with wide-field optical coherence tomography (OCT). This enables high-resolution, real-time evaluation of excised tumor margins, offering ten times the resolution of standard x-ray and ultrasound at an imaging depth of 2 mm—crucial for assessing breast cancer margins. The AI component of Claire™ was developed using Perimeter's extensive library of more than two million breast tissue images, thereby enhancing the device's ability to aid surgeons in identifying challenging-to-detect cancer.

"We're excited to introduce Claire publicly for the first time at the highly regarded ASBrS meeting of more than 1,700 surgeons and healthcare professionals," stated Perimeter CEO Adrian Mendes. "By combining AI with OCT imaging, Claire has the potential to enhance surgical decision-making, improve precision, and potentially reduce the need for repeat surgeries."

The system is designed as an adjunct to three-dimensional imaging and is intended to complement standard methods for evaluating the margins of excised lumpectomy tissue. However, it is not a replacement for standard tissue histopathology assessment.

The FDA approval for Claire™ marks a significant step for Perimeter as the company aims to transform cancer surgery with advanced imaging tools. Attendees of the ASBrS annual meeting were invited to Booth #325 to witness live demonstrations of the Claire™ OCT+AI, highlighting its capabilities as a cutting-edge addition to breast cancer surgeries.